Ultrasonographic and biochemical evaluation of visceral obesity in obese women with non-alcoholic fatty liver disease.
OBJECTIVE
Identification of specific origin of lipid accumulation in the liver of patients with non-alcoholic fatty liver disease (NAFLD) is the most important step in preventing this condition. Because liver steatosis, in the obese patients without any systemic disease, can be graded easily by ultrasonography (US), we aimed to demonstrate the degree of liver steatosis and abdominal fat distribution by US, furthermore evaluate biochemical, anthropometrical measurements, and define the possible relationship between these parameters in obese women with different grades of liver steatosis.


METHODS
In this controlled clinical study, according to US evaluation of liver steatosis, the patients were divided into four groups: control (no steatosis), mild, moderate and severe steatosis groups. Demographic, biochemical and anthropometric measurements were done. Insulin resistance was determined by using homeostasis model assessment (HOMA-IR). Liver steatosis and abdominal fat distributions were evaluated by US.


RESULTS
The subcutaneous and preperitoneal fat layer measurements did not show any significant difference between the groups. The visceral fat layer thickness was significantly higher in severe liver steatosis group compared to the control and steatosis groups. The highest serum fasting insulin, uric acid levels and HOMA-IR index were observed in the severe liver steatosis group. Visceral fat thickness was positively correlated with serum UA levels and HOMA-IR CONCLUSIONS: This study suggests that visceral adipose tissue, HOMA-IR and serum uric acid levels are the main determinants of NAFLD in obese patients.
Fenkci
Semin
S
Department of Internal Medicine, Division of Endocrinology and Metabolism, Pamukkale University School of Medicine, 2 Daire: 4 Bagbasi, Denizli, Turkey. sfenkci@yahoo.com
Rota
S
S
Sabir
N
N
Akdag
B
B
D000328:Adult; D000367:Age Factors; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D015992:Body Mass Index; D005234:Fatty Liver / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000000981:diagnostic imaging* / Q000473:pathology; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging*; D050507:Subcutaneous Fat, Abdominal / Q000000981:diagnostic imaging; D014463:Ultrasonography; D014527:Uric Acid / Q000097:blood; D049629:Waist-Hip Ratio; D005723:gamma-Glutamyltransferase / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D014527:Uric Acid; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase